BGLC VS JAGX Stock Comparison

Performance

BGLC
10/100

BGLC returned -97.12% in the last 12 months. Based on SPY's performance of -13.73%, its performance is below average giving it a score of 10 of 100.

JAGX
10/100

JAGX returned -96.90% in the last 12 months. Based on SPY's performance of -21.29%, its performance is below average giving it a score of 10 of 100.

Profit

BGLC
33/100

Out of the last 18 quarters, BGLC has had 6 profitable quarters and has increased their profits year over year on 4 of them.

JAGX
10/100

Out of the last 20 quarters, JAGX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

BGLC
56/100

BGLC has had a higher than average amount of volatility over the last 12 months giving it a score of 56 of 100.

JAGX
54/100

JAGX has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

Analyst Price Targets

BGLC

"Analyst Price Targets" not found for BGLC

JAGX
75/100

1 analysts offer 12-month price targets for JAGX. Together, they have an average target of 0, the most optimistic target put JAGX at 0 within 12-months and the most pessimistic has JAGX at 0.

Sentiment

BGLC

"Sentiment" not found for BGLC

JAGX
70/100

JAGX had a bullish sentiment score of 69.95% across Twitter and StockTwits over the last 12 months. It had an average of 251.11 posts, 260.33 comments, and 684.97 likes per day.

Technicals

BGLC

"Technicals" not found for BGLC

JAGX
21/100

JAGX receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

BGLC

"Earnings" not found for BGLC

JAGX
10/100

JAGX has missed earnings 12 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

BioNexus Gene Lab Corp Common stock Summary

Nasdaq / BGLC

Healthcare

Medical - Diagnostics & Research

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Jaguar Health, Inc. Summary

Nasdaq / JAGX

Healthcare

Biotechnology

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Power up your portfolio